Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Abraham

Showing results (891-900 of 932) with videos related to

Pageof 94
Sort By:
JACC. Heart Failure|November 17, 2020
Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research ConsortiumWilliam T Abraham, Mitchell A Psotka, Mona Fiuzat, et al.
Plos One|October 17, 2012
Combinatorial pharmacogenetic interactions of bucindolol and β1, α2C adrenergic receptor polymorphismsChristopher M O'Connor, Mona Fiuzat, Peter E Carson, et al.
European Journal of Heart Failure|May 10, 2026
Safety and Feasibility of the eLymTM System for Interstitial Decongestion in Acute Decompensated Heart Failure: Primary results of the DELTA-HF trialJorge Nuche, María Dolores García-Cosío Carmena, Jan Biegus, et al.
European Journal of Heart Failure|October 5, 2020
Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research ConsortiumWilliam T Abraham, Mitchell A Psotka, Mona Fiuzat, et al.
Journal of the American Heart Association|June 11, 2025
Race and Ethnicity in Heart Failure Trials: Time to Update Recommended Categories for Global RelevanceMingming Yang, Toru Kondo, Pooja Dewan, et al.
Circulation. Cardiovascular Quality and Outcomes|June 18, 2024
American Heart Association Cardiogenic Shock Registry: Design and ImplementationDavid A Morrow, Mariell Jessup, William T Abraham, et al.
American Heart Journal|October 31, 2007
Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trialArthur M Feldman, Ron M Oren, William T Abraham, et al.
European Heart Journal|December 22, 2020
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetesWilliam T Abraham, JoAnn Lindenfeld, Piotr Ponikowski, et al.
JACC. Heart Failure|December 1, 2022
Functional and Symptomatic Clinical Trial Endpoints: The HFC-ARC Scientific Expert PanelMitchell A Psotka, William T Abraham, Mona Fiuzat, et al.
American Heart Journal|August 23, 2018
Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trialMichael J Mack, William T Abraham, JoAnn Lindenfeld, et al.
Pageof 94

Showing results (891-900 of 932) with videos related to

Sort By:
Pageof 94
JACC. Heart Failure|November 17, 2020
Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research ConsortiumWilliam T Abraham, Mitchell A Psotka, Mona Fiuzat, et al.
Plos One|October 17, 2012
Combinatorial pharmacogenetic interactions of bucindolol and β1, α2C adrenergic receptor polymorphismsChristopher M O'Connor, Mona Fiuzat, Peter E Carson, et al.
European Journal of Heart Failure|May 10, 2026
Safety and Feasibility of the eLymTM System for Interstitial Decongestion in Acute Decompensated Heart Failure: Primary results of the DELTA-HF trialJorge Nuche, María Dolores García-Cosío Carmena, Jan Biegus, et al.
European Journal of Heart Failure|October 5, 2020
Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research ConsortiumWilliam T Abraham, Mitchell A Psotka, Mona Fiuzat, et al.
Journal of the American Heart Association|June 11, 2025
Race and Ethnicity in Heart Failure Trials: Time to Update Recommended Categories for Global RelevanceMingming Yang, Toru Kondo, Pooja Dewan, et al.
Circulation. Cardiovascular Quality and Outcomes|June 18, 2024
American Heart Association Cardiogenic Shock Registry: Design and ImplementationDavid A Morrow, Mariell Jessup, William T Abraham, et al.
American Heart Journal|October 31, 2007
Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trialArthur M Feldman, Ron M Oren, William T Abraham, et al.
European Heart Journal|December 22, 2020
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetesWilliam T Abraham, JoAnn Lindenfeld, Piotr Ponikowski, et al.
JACC. Heart Failure|December 1, 2022
Functional and Symptomatic Clinical Trial Endpoints: The HFC-ARC Scientific Expert PanelMitchell A Psotka, William T Abraham, Mona Fiuzat, et al.
American Heart Journal|August 23, 2018
Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trialMichael J Mack, William T Abraham, JoAnn Lindenfeld, et al.
Pageof 94